ILiAD Biotechnologies
ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial
June 25, 2024Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough
ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
